(NASDAQ: ONC) Beone Medicines's forecast annual revenue growth rate of 16.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Beone Medicines's revenue in 2025 is $4,562,002,000.On average, 5 Wall Street analysts forecast ONC's revenue for 2025 to be $7,460,223,313,164, with the lowest ONC revenue forecast at $7,394,599,230,894, and the highest ONC revenue forecast at $7,533,768,801,037. On average, 6 Wall Street analysts forecast ONC's revenue for 2026 to be $8,948,514,963,154, with the lowest ONC revenue forecast at $8,421,320,960,963, and the highest ONC revenue forecast at $9,289,311,339,918.
In 2027, ONC is forecast to generate $10,394,521,926,902 in revenue, with the lowest revenue forecast at $9,178,274,345,683 and the highest revenue forecast at $11,533,669,543,376.